A Clinical Study on the Combination of Shuxian Anshen Formula and Micro-needle Acupuncture for the Treatment of Androgenetic Alopecia (Stagnation of Liver Qi Syndrome)

注册号:

Registration number:

ITMCTR2024000604

最近更新日期:

Date of Last Refreshed on:

2024-10-23

注册时间:

Date of Registration:

2024-10-23

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

疏肝安神方联合微针针刺治疗雄激素源性脱发(肝郁气滞证)的临床研究

Public title:

A Clinical Study on the Combination of Shuxian Anshen Formula and Micro-needle Acupuncture for the Treatment of Androgenetic Alopecia (Stagnation of Liver Qi Syndrome)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

疏肝安神方联合微针针刺治疗雄激素源性脱发(肝郁气滞证)的临床研究

Scientific title:

A Clinical Study on the Combination of Shuxian Anshen Formula and Micro-needle Acupuncture for the Treatment of Androgenetic Alopecia (Stagnation of Liver Qi Syndrome)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

熊艺

研究负责人:

何翔

Applicant:

xiong yi

Study leader:

he xiang

申请注册联系人电话:

Applicant telephone:

18201860743

研究负责人电话:

Study leader's telephone:

13681737694

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

969602590@qq.com

研究负责人电子邮件:

Study leader's E-mail:

heroxiang@hotmail.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区华佗路678弄17幢1号楼204室

研究负责人通讯地址:

上海市张衡路528号

Applicant address:

No. 204 Building 1 Block 17 Huatuo Road Pudong New Area Shanghai

Study leader's address:

No. 528 Zhang Heng Road Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学

Applicant's institution:

Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-1503-086-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属曙光医院伦理委员会

Name of the ethic committee:

EC of Shuguang Hospital afiliated to Shanghai University of TMC

伦理委员会批准日期:

Date of approved by ethic committee:

2024/5/15 0:00:00

伦理委员会联系人:

马俊坚

Contact Name of the ethic committee:

Ma Jun Jian

伦理委员会联系地址:

上海市张衡路528号

Contact Address of the ethic committee:

No. 528 Zhang Heng Road Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-20256070

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sgyyllwyh@126.com

研究实施负责(组长)单位:

曙光医院

Primary sponsor:

Shuguang Hospital

研究实施负责(组长)单位地址:

上海市张衡路528号

Primary sponsor's address:

No. 528 Zhang Heng Road Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

浦东新区

Country:

China

Province:

Shanghai

City:

Pudong New District

单位(医院):

曙光医院

具体地址:

上海市张衡路528号

Institution
hospital:

Shuguang Hospital

Address:

No. 528 Zhang Heng Road Shanghai

经费或物资来源:

自筹

Source(s) of funding:

elf-financing

研究疾病:

雄激素性脱发

研究疾病代码:

Target disease:

Androgenic alopecia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究的目的是为了评价疏肝安神方联合微针针刺治疗雄激素源性脱发(肝郁气滞证)的有效性和安全性,其研究结果将用于为治疗雄激素源性脱发患者提供一种更有效的方法。

Objectives of Study:

The purpose of this study is to evaluate the efficacy and safety of Shuguan Anshen Formula combined with micro-acupuncture in treating male pattern hair loss (with liver qi stagnation syndrome) and the research results will be used to provide a more effective method for treating male pattern hair loss patients.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)符合《临床皮肤病学》雄激素源性脱发的诊断标准的患者。 2)符合参照《中医外科学》发蛀脱发肝郁气滞辨证标准制定患者。 3)年龄18 ~ 50岁,性别不限; 4)同意参加临床试验观察及能配合按期随访者。

Inclusion criteria

1) Patients who meet the diagnostic criteria of androgenic alopecia in Clinical Dermatology. 2) Patients who meet the criteria for syndrome differentiation of liver-qi stagnation with reference to "Traditional Chinese Surgery". 3) Age 18-50 years old gender is not limited; 4) Agree to participate in clinical trial observation and can cooperate with the regular interview.

排除标准:

1)不符合上述纳入标准者。 2)孕妇和哺乳期妇女。 3)对本研究中药物过敏者。 4)严重过敏体质者。 5)合并有严重的心脑血管疾病、肝肾功能不全、血液系统疾病、自身免疫性疾病、精神疾病者。 6)拒绝配合治疗、随访者。

Exclusion criteria:

1) Those who do not meet the above inclusion criteria. 2) Pregnant and lactating women. 3) Patients with drug allergy in this study. 4) People with severe allergies. 5) Patients with severe cardiovascular and cerebrovascular diseases liver and kidney insufficiency blood system diseases autoimmune diseases and mental diseases. 6) Refuse to cooperate with the treatment accompanied by visitors.

研究实施时间:

Study execute time:

From 2024-03-01

To      2024-12-31

征募观察对象时间:

Recruiting time:

From 2024-05-15

To      2024-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

38

Group:

control group

Sample size:

干预措施:

微针针刺

干预措施代码:

Intervention:

microneedle acupuncture

Intervention code:

组别:

试验组

样本量:

38

Group:

Experimental group

Sample size:

干预措施:

口服中药

干预措施代码:

Intervention:

Oral Chinese medicine

Intervention code:

样本总量 Total sample size : 76

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海市

市(区县):

浦东新区

Country:

China

Province:

Shanghai

City:

单位(医院):

曙光医院

单位级别:

三甲

Institution/hospital:

Shuguang Hospital

Level of the institution:

Third-class hospital

测量指标:

Outcomes:

指标中文名:

新生发数量

指标类型:

主要指标

Outcome:

Number of new hair

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁量表

指标类型:

次要指标

Outcome:

SDS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 50
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究员熊艺使用SPSS产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Researcher Xiong Yi used SPSS to generate random sequences

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025.01.01 数据上传至ResMan临床试验公共管理平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2025.01.01 Data upload to Clinical Trial Management Public Platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.数据采集:本实验的CRF表格 2.数据管理:ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data collection: CRF table of this experiment 2. Data management: ResMan

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above